Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes leaving the study early ‐ short term Rate of attrition compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes adverse effects: general ‐ movement disorders ‐ requiring… compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with anaemia
It is very uncertain whether parenteral iron changes mortality compared with oral iron (very low certainty).
1 finding from 1 review
Blood transfusion · patients with anaemia
It is very uncertain whether parenteral iron changes proportion requiring blood transfusion compared with oral iron (very low certainty).
1 finding from 1 review
Amount of blood transfused per patient (in units) · patients with anaemia
1 finding from 1 review
Haemoglobin (g/dL) · patients with anaemia
1 finding from 1 review
Quality of life · patients with anaemia
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether parenteral iron changes serious adverse events compared with oral iron (very low certainty).
1 finding from 1 review
Asthma relapse1at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in asthma relapse1at 16 to 21 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hospital admission compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hoarseness at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hoarseness at 16 to 21 days compared with oral corticosteroid (low certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in symptomatic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Endoscopic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review